Log In Sign up
The largest database of trusted experimental protocols

Anti pd 1

Manufactured by Merck Group
Visit Supplier
Sourced in Germany

Anti-PD-1 is a laboratory equipment product used for research purposes. It functions as a monoclonal antibody that binds to the PD-1 protein, which is involved in the regulation of the immune system. The core function of Anti-PD-1 is to enable researchers to study the role of the PD-1 pathway in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Anti pd l1, by Thermo Fisher Scientific (2 mentions) Anti ki67, by Agilent Technologies (2 mentions) Anti cd4, by StatLab (2 mentions) Anti cd8, by StatLab (2 mentions) Anti cd68, by Leica (2 mentions) Anti cd20, by Leica (2 mentions) Anti lag3, by Cell Signaling Technology (2 mentions) Cd244, by Proteintech (2 mentions) Cd160, by Abcam (2 mentions) Anti cd45ro, by Thermo Fisher Scientific (2 mentions) Cisplatin, by Merck Group (1 mentions) Cisplatin cis, by Merck Group (1 mentions) Isotype igg, by BioXCell (1 mentions) Anti pd 1, by BioXCell (1 mentions) Anti cd3, by Merck Group (1 mentions) Anti cd8, by Merck Group (1 mentions) Anti cd45, by Merck Group (1 mentions) Fluorescence microscope, by Nikon (1 mentions) Anti ha, by Merck Group (1 mentions) Anti p shp 1, by Abcam (1 mentions)

Spelling variants of this product

Nivolumab (anti-PD-1) (2 citations) Anti–PD-1 alone (clone G4, (2 citations)

7 protocols using anti pd 1

1

Apoptosis Detection in Co-Cultured Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
K7M2 cells treated with lentiviral transfection were suspended and cultured in a 6-well plate. After 12 h, the CD4+PD-1+ lymphocyte were co-cultured with K7M2 cells. The cells were then divided into four groups, including the control, anti-PD-1 antibody (Anti-PD-1), cisplatin (Cis; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and anti-PD-1 antibody combined with cisplatin (anti-PD-1+ Cis) groups. These co-cultured cells were collected and resuspended in 500 μl binding buffer for apoptosis detection following treatment for 24 h. Next, annexin V-fluorescein isothiocyanate (FITC; 5 μl) and propidium iodide (PI; 5 μl) were added to the cell suspension and incubated for 10 min at room temperature in the dark; they were then detected within 1 h using FACSCalibur™ Flow Cytometer.
Liu X., He S., Wu H., Xie H., Zhang T, & Deng Z. (2019). Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environmental Health and Preventive Medicine, 24, 79.
+ Open protocol
+ Expand
2

Combination Therapy with Anti-PD-1 and Temozolomide in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For combination therapy experiments, mice in the anti-PD-1/Temozolomide combined group were given TMZ (Sigma-Aldrich, Madrid, Spain) 60 mg/kg by intragastric administration and anti-PD-1 (Bio X cell, Lebanon, NH, USA) 100 μg/dose via intra-peritoneal injection on the same day, both therapies administered in IMS (every 6 days) from day 11 post-implantation until tumour escape from therapy. Mice in the monotherapy groups received equivalent doses of drugs and control mice received equivalent doses of isotype IgG (Bio X cell, Lebanon, NH, USA) according to the same dosing schedule.
For high dosage (500/250 μg) anti-PD-1 monotherapy experiment, see specific result sections for the detailed anti-PD-1 administration scheme. After treatment, animals meeting endpoint criteria were euthanized by cervical dislocation according to animal welfare protocol advice for ethical reasons. In all the therapy strategies, cured mice were followed up and a re-challenge experiment was carried out (for further details, see Section 4.5).
Wu S., Calero-Pérez P., Arús C, & Candiota A.P. (2020). Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches. International Journal of Molecular Sciences, 21(22), 8775.
+ Open protocol
+ Expand
3

Immunohistochemical Analysis of Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
Archival tissue from the autopsy was obtained and IHC evaluation was performed. Antibodies utilized were anti-CD45RO (Thermo Scientific, cat# MA5–11532, 1:1,600), anti-GZMB (Granzyme B, Biocare cat# ACI 3202 AA, prediluted), anti-Ki67 (Dako, cat# M7240, 1:200), anti-CD4 (StatLab, cat# RM27–10, prediluted), anti-CD8 (StatLab, cat# MM39–10, prediluted), anti-PD-L1 (Cat.#PA5–28115 ThermoFisher, Grand Island, NY; 1:7500), anti-CD68 (PA0191, Leica, Buffalo Grove, IL; prediluted), anti-PD-1 (HPA035981, Sigma-Aldrich Co., St. Louis, MO; 1:75), anti-CD20 (PA0906, Leica, Buffalo Grove, IL, prediluted), anti-LAG3 (Cell Signaling, Catalog# 15372, dilution 1:200), CD244 (Proteintech, Catalog# 16677–1-AP, dilution 1:200), CD160 (Abcam, Catalog# ab202845, dilution 1:600). The Bond Polymer Refine detection system or Envision system was used for visualization. Slides were then dehydrated, cleared, and coverslipped.
Johnson D.B., McDonnell W.J., Ericsson-Gonzalez P.I., Al-Rohil R., Mobley B.C., Salem J.E., Wang D.Y., Sanchez V., Wang Y., Chastain C.A., Barker K., Liang Y., Warren S., Beechem J., Menzies A.M., Tio M., Long G.V., Cohen J.V., Guidon A.C., O’Hare M., Chandra S., Chowdhary A., Lebrun-Vignes B., Goldinger S., Rushing E., Buchbinder E., Mallal S.A., Shi C., Xu Y., Moslehi J.J., Sanders M.E., Sosman J.A, & Balko J.M. (2019). A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature medicine, 25(8), 1243-1250.
+ Open protocol
+ Expand
4

Immunohistochemical Analysis of Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
Archival tissue from the autopsy was obtained and IHC evaluation was performed. Antibodies utilized were anti-CD45RO (Thermo Scientific, cat# MA5–11532, 1:1,600), anti-GZMB (Granzyme B, Biocare cat# ACI 3202 AA, prediluted), anti-Ki67 (Dako, cat# M7240, 1:200), anti-CD4 (StatLab, cat# RM27–10, prediluted), anti-CD8 (StatLab, cat# MM39–10, prediluted), anti-PD-L1 (Cat.#PA5–28115 ThermoFisher, Grand Island, NY; 1:7500), anti-CD68 (PA0191, Leica, Buffalo Grove, IL; prediluted), anti-PD-1 (HPA035981, Sigma-Aldrich Co., St. Louis, MO; 1:75), anti-CD20 (PA0906, Leica, Buffalo Grove, IL, prediluted), anti-LAG3 (Cell Signaling, Catalog# 15372, dilution 1:200), CD244 (Proteintech, Catalog# 16677–1-AP, dilution 1:200), CD160 (Abcam, Catalog# ab202845, dilution 1:600). The Bond Polymer Refine detection system or Envision system was used for visualization. Slides were then dehydrated, cleared, and coverslipped.
Johnson D.B., McDonnell W.J., Ericsson-Gonzalez P.I., Al-Rohil R., Mobley B.C., Salem J.E., Wang D.Y., Sanchez V., Wang Y., Chastain C.A., Barker K., Liang Y., Warren S., Beechem J., Menzies A.M., Tio M., Long G.V., Cohen J.V., Guidon A.C., O’Hare M., Chandra S., Chowdhary A., Lebrun-Vignes B., Goldinger S., Rushing E., Buchbinder E., Mallal S.A., Shi C., Xu Y., Moslehi J.J., Sanders M.E., Sosman J.A, & Balko J.M. (2019). A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature medicine, 25(8), 1243-1250.
+ Open protocol
+ Expand
5

Multimodal Immunotherapy in Mouse Cancer Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
We used the following monoclonal antibodies: anti-VEGFA (B20-4.1 mouse IgG2a, 10 mg/kg, Roche); anti-ANGPT2 (murinized LC06 IgG2a, 10 mg/kg, Roche); anti-VEGFA/ANGPT2 (murinized A2V IgG2a, 20 mg/kg, Roche); anti-PD-1 (Rat IgG2a, clone RMPI-14, 10 mg/kg, BE0146 BioXCell), anti-PD-1mut (murine IgG2a PGLALA, 10mg/kg, Roche), anti-PD-L1 (murine IgG1, clone 6E11, 10mg/kg, Roche), and anti-CSF1R (mouse-hamster chimeric IgG1, clone 2G2, 30mg/kg, Roche). Control IgGs were mouse IgG1 (clone MOPC-21; 20-30 mg/kg, Roche), used for B20, LC06, A2V and anti-CSF1R; and rat IgG2a (clone 2A3; 10 mg/kg, BE0089 BioXCell), for anti-PD-1. Therapeutic antibodies and control IgGs were administered once weekly for 3-4 weeks from week 15 post-transduction in KP and KPM mice and week 27 in KPO mice. SV2 tumor-bearing mice were treated once per week for 2 weeks from day 12 post-tumor injection. Rat anti-CD8α depleting mAbs (clone 53-6.7 IgG2a; BioXCell, 4mg/kg) and control rat IgG2a (clone 2A3; 4mg/kg) were administered 3 times per week for 4 weeks, starting at day -3 before treatment initiation. Cisplatin (7 mg/kg, or 3.5 mg/kg when combined with A2V and anti-PD-1; Sigma-Aldrich) was administered once per week for 2 weeks and, following 1 week of break, once per week for another 2 weeks. All therapeutic agents were diluted in sterile PBS and administered i.p.
Martinez-Usatorre A., Kadioglu E., Boivin G., Cianciaruso C., Guichard A., Torchia B., Zangger N., Nassiri S., Keklikoglou I., Schmittnaegel M., Ries C.H., Meylan E, & De Palma M. (2021). Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science translational medicine, 13(606), eabd1616.
+ Open protocol
+ Expand
6

Quantification of PD-L1 and PD-1 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
The cell surface PD‐L1 expression in the cells were detected by flow cytometry. Cells following various treatments were gently trypsinized and collected by centrifugation. After washed twice with PBS, cells were stained with an anti-PD-L1 antibody (ABF133; Sigma-Aldrich) and anti-STOML2 antibody (ab191883, Abcam). To quantify PD-1 expression on CD8+ T cells, whole blood into an EDTA tube was collected and subjected to red blood cell lysis followed by and collected by centrifugation. Cell pellets were subsequently stained with different antibodies for flow cytometry analysis. Cell populations were discriminated by the following antibodies: anti-CD45 (SAB4700587; Sigma-Aldrich), anti-CD3 (SAB4700044; Sigma-Aldrich), anti-CD8 (SAB4700084; Sigma-Aldrich), and anti-PD1 (SAB5701115; Sigma-Aldrich). Cell populations and marker expression were gated and analyzed using the FlowJo software: leukocytes (CD45+), T lymphocytes (CD45+CD3+), and CD8+ T cells (CD45+CD3+CD8+).
Gong H., Chen S., Liu S., Hu Q., Li Y., Li Y., Li G., Huang K., Li R, & Fang L. (2024). Overexpressing lipid raft protein STOML2 modulates the tumor microenvironment via NF-κB signaling in colorectal cancer. Cellular and Molecular Life Sciences: CMLS, 81(1), 39.
+ Open protocol
+ Expand
7

Immunohistochemical Analysis of Spinal Cord and DRG

Check if the same lab product or an alternative is used in the 5 most similar protocols
After appropriate survival times, mice were anesthetized with isoflurane. Spinal cord (L4-L5)/DRG (L3–L5) segments were obtained after perfusion with phosphate-buffered saline (PBS) and 4% paraformaldehyde. The tissues were postfixed in 4% paraformaldehyde and cryoprotected in a 30% sucrose solution. The tissues were embedded inoptimal cutting temperature (OCT) compound medium in advance and sliced into transverse sections (spinal cord sections, 30 μm; DRG sections, 12 μm) with a microtome. After blocking in 3% BSA for 2 h, the sections were incubated overnight at 4 °C with the following primary antibodies: anti–PD-1 (1:500, Sigma, rabbit)/anti-HA (1:2,000, Sigma, rabbit)/anti–pSHP-1(1:500, Abcam, rabbit)/IBA 1 (1:1,000, NOVUS, goat). After washing with PBS, the sections were incubated with a Cy3-conjugated secondary antibody (1:1,000) overnight at 4 °C. Images were captured with a Nikon fluorescence microscope.
Zhao L., Luo H., Ma Y., Zhu S., Wu Y., Lu M., Yao X., Liu X, & Chen G. (2022). An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects. Proceedings of the National Academy of Sciences of the United States of America, 119(31), e2204114119.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!